Immunocore (IMCR)
(Delayed Data from NSDQ)
$38.29 USD
+0.83 (2.22%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $38.25 -0.04 (-0.10%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Brokerage Reports
0 items in cart
Immunocore Holdings PLC Sponsored ADR [IMCR]
Reports for Purchase
Showing records 1 - 20 ( 32 total )
Company: Immunocore Holdings PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
ASCO Takeaways: PRAME Bispecific Achieves Durable Disease Control in Cutaneous Melanoma
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Immunocore Holdings PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
TEBE-AM Converts to Phase 3, Placing Data Readout on Track for 2026 in Cutaneous Melanoma; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Immunocore Holdings PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
ASCO Takeaways: Promising Clinical Activity With Lead PRAME Bispecific Program in Cutaneous Melanoma; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Immunocore Holdings PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
KIMMTRAK Does Not Miss a Beat; PRAME Franchise Poised to Shine at ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Immunocore Holdings PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Key Takeaway From Biotech Breakthroughs Oncology Event: The Rise of PRAME-Targeted Therapies
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Immunocore Holdings PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Pipeline and Commercialization Efforts Firing on All Cylinders; 4Q23 Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Immunocore Holdings PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Hepatitis B Breakthrough Boom: Navigating a $450-$500 Billion Frontier
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Immunocore Holdings PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Differentiated Bispecific Biologics Pipeline on Track in Oncology, Infectious Disease, and Autoimmunity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Immunocore Holdings PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Multiple PRAME Readouts Expected in 2024; Pipeline Expansion on Track Including to Autoimmunity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Immunocore Holdings PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for IMCR 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Immunocore Holdings PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
3Q23 Results; KIMMTRAK Launch Impresses; Pipeline Advances
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Immunocore Holdings PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
HBV Conference Takeaways: Lead Program Advancing Through Phase 1 With Next Updates on Track for 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Immunocore Holdings PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
ESMO Data Support Long-Term Survival Benefit of KIMMTRAK in Uveal Melanoma; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Immunocore Holdings PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Key Takeaways From 25th Annual Global Conference: Multiple Underappreciated Programs to Shine in 2H23 and 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Immunocore Holdings PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
KIMMTRAK Launch Progressing; PRAME Program Expanding; Momentum Building Ahead of Next Catalysts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Immunocore Holdings PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
2Q23 Results; PRAME Advances to Phase 3 in Cutaneous Melanoma; KIMMTRAK Launch and Pipeline on Track; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Immunocore Holdings PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: Immunocore Holdings PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Management Meeting Highlights Year of Execution in 2023 Ahead of Many Expected Catalysts in 2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Immunocore Holdings PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
AACR Data Details KIMMTRAK''s Differentiation in Uveal Melanoma; Compelling Preclinical Data Emerges; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Immunocore Holdings PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Maintains Momentum on KIMMTRAK; Expands PRAME; Impresses With Initial HIV Data; Exits MAGE; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P